Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MRNA
MRNA logo

MRNA News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

MRNA News

mRNA Vaccine Stocks Rise as HHS Committee Revises Recommendations

10h agoseekingalpha

BioNTech's Strategic Shift and Clinical Progress

1d agoBenzinga

BioNTech Announces Earnings, But That's Not the Reason for the 17% Drop in Stock Price.

1d agoBarron's

FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks

2d agoBenzinga

Surge in Oil Prices Triggers Market Turmoil

2d agoCNBC

uniQure Shares Surge Following FDA Official's Departure

2d agoBenzinga

Dr. Vinay Prasad to Depart FDA Amid Controversial Tenure

5d agoBenzinga

FDA Vaccine Chief Vinay Prasad to Depart Agency

5d agostocktwits

MRNA Events

03/09 16:30
Moderna Shares Rise 5.85% to $55.59
Moderately bullish activity in Moderna (MRNA), with shares up $3.08, or 5.85%, near $55.59. Options volume relatively light with 51k contracts traded and calls leading puts for a put/call ratio of 0.94, compared to a typical level near 0.48. Implied volatility (IV30) is higher by 3.7 points near 78.89,in the top quartile of the past year, suggesting an expected daily move of $2.76. Put-call skew steepened, indicating increased demand for downside protection.
03/09 10:00
Live Nation and Other Liquid Option Stocks Gain
Notable gainers among liquid option names this morning include Live Nation (LYV) $165.28 +9.16, Moderna (MRNA) $55.38 +2.85, Dow Chemical (DOW) $34.92 +1.64, CF Industries (CF) $118.66 +2.88, and LyondellBasell (LYB) $68.62 +1.52.
03/08 22:30
KKR Plans to Sell CoolIT Systems for Over $3B
Catch up on the weekend's top five stories with this list compiled by The Fly: 1) KKR (KKR) is working on a sale of CoolIT Systems, hoping to fetch a price tag in excess of $3B, Oliver Barnes and Antoine Gara of The Financial Times reports, citing people familiar with the matter. This is a massive increase from the unit's $270M valuation when KKR bought a majority stake in 2023. 2) Dr. Vinay Prasad, who issued several controversial decisions, including having refused to accept Moderna's (MRNA) application for a new mRNA flu vaccine and refused an application for a Huntington's drug's review from UniQure (QURE), is leaving the agency at the end of April, reported The New York Times' Christina Jewett on Friday evening, citing a Health and Human Services spokesman. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks that could be impacted by the news include Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Moderna (MRNA), Novavax (NVAX) and Lexeo Therapeutics (LXEO). 3) Plug Power (PLUG) plans to offer hydrogen electricity, as much as 250 megawatts, in an auction President Donald Trump is eager to make happen later this year, Will Wade and Naureen Malik of Bloomberg reports, citing chairman Andy Marsh. PJM Interconnection, which is facing power shortages due to surging consumption by data centers to power AI, has been urged by the Trump administration to hold an emergency auction to bolster supplies. 4) Prudential (PRU) disclosed yesterday that on March 6, the Prudential Gibraltar Financial Life Insurance Co., a subsidiary of Prudential Financial, issued a press release in Japan reporting instances of the unauthorized removal of information by certain employees of PGFL seconded to financial institutions in Japan. The investigation confirmed that 11 employees in total removed 379 instances of information at seven contracted agencies. The removed information pertained to operational matters such as sales performance at the assigned agencies. "After confirming the content of all cases with the agencies, no issues were identified that would raise concerns under the Unfair Competition Prevention Act, nor was there any inappropriate removal of contract information," Prudential Gibraltar Financial said. 5) Activist investor Starboard Value has built a stake in Lamb Weston (LW) and has been pushing to company to speed up improvements and cost cutting to boost stock performance, Lauren Thomas of The Wall Street Journal reports, citing people familiar with the matter. Starboard is now one of the largest shareholders in the company, the sources added.
03/08 17:00
Dr. Vinay Prasad to Leave Agency at End of April
Dr. Vinay Prasad, who issued several controversial decisions, including having refused to accept Moderna's (MRNA) application for a new mRNA flu vaccine and refused an application for a Huntington's drug's review from UniQure (QURE), is leaving the agency at the end of April, reported The New York Times' Christina Jewett on Friday evening, citing a Health and Human Services spokesman. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks that could be impacted by the news include Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Avidity Biosciences (RNA), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Moderna (MRNA), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

MRNA Monitor News

Moderna Settles Patent Dispute, Stock Rises Amid Positive Market Reaction

Mar 09 2026

Moderna settles patent dispute, stock reacts negatively amid market decline

Mar 06 2026

Moderna settles patent dispute, stock reacts negatively amid market decline

Mar 05 2026

Moderna Settles Patent Dispute, Boosting Market Confidence

Mar 04 2026

Moderna's mCombriax Vaccine Recommended by EMA Amid Revenue Decline

Mar 03 2026

Moderna's Flu Vaccine Application Accepted by FDA for Review

Feb 23 2026

Moderna's Flu Vaccine Application Accepted by FDA for Review

Feb 19 2026

Moderna's mRNA-1010 Marketing Application Accepted by FDA

Feb 18 2026

MRNA Earnings Analysis

Moderna Q3 2025 Earnings: Strategic Insights Unveiled- Intellectia AI™
4 months ago
Resilient Path Ahead - Intellectia AI™
1 years ago
Moderna Inc Reports Strong Financial Results for Third Quarter 2024
1 years ago

People Also Watch